Question | Discussion | References | CME Credit

Case 4: References

  1. Saag MS, Tebas P, Sension M, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS. 2001;15:1971-8.
    [The following link will open in a new window. PubMed Abstract]
  2. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr. 2001;27:350-64.
    [The following link will open in a new window. PubMed Abstract]
  3. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-46.
    [The following link will open in a new window. PubMed Abstract]
  4. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32.
    [The following link will open in a new window. PubMed Abstract]
  5. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 4, 2006. Available at:
    [The following link will open in a new window. AIDSinfo - Accessed June 30, 2006]
  6. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 1998;42:2637-44.
    [The following link will open in a new window. PubMed Abstract]
  7. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
    [The following link will open in a new window. PubMed Abstract]
  8. Tsuchiya K, Matsuoka-Aizawa S, Yasuoka A, et al. Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naive patients treated with NFV-containing regimens in an HIV clinic cohort. J Clin Virol. 2003;27:252-62.
    [The following link will open in a new window. PubMed Abstract]
  9. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med. 2003;4:38-47.
    [The following link will open in a new window. PubMed Abstract]
  10. Clotet B, Ruiz L, Martinez-Picado J, Negredo E, Hill A, Popescu M. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials. 2002;3:316-23.
    [The following link will open in a new window. PubMed Abstract]
  11. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001;15:609-15.
    [The following link will open in a new window. PubMed Abstract]
  12. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88.
    [The following link will open in a new window. PubMed Abstract]
  13. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-8.
    [The following link will open in a new window. PubMed Abstract]
  14. Saah AJ, Haas DW, DiNubile MJ, et al. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. J Infect Dis. 2003;187:1157-62.
    [The following link will open in a new window. PubMed Abstract]
  15. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744-52.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 4 Question | Back to Discussion]

CME Credit | Back to Top